# The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study

> **NCT00599222** · PHASE3 · COMPLETED · sponsor: **Anders Kvanta** · enrollment: 100 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** ranibizumab
- **PROCEDURE:** TTT
- **PROCEDURE:** Sham TTT

## Key facts

- **NCT ID:** NCT00599222
- **Lead sponsor:** Anders Kvanta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-11
- **Final completion:** 2010-02
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2011-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00599222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00599222, "The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00599222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*